Search Results

Syntron's QuikStrip One Step Cocaine assay is a rapid, qualitative, competitive binding immunoassay for the determination of Cocaine in urine at the NIDA recommended cutoff of 300 ng/ml by GC/MS. (NIDA screening cutoff is 300 ng/ml) The test provides only preliminary data which should be confirmed by other methods such as gas chromatography/mass spectrophotometry (GC/MS). Clinical considerations and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicatedf. Syntron's QuikStrip One Step Cocaine Test is not intended to monitor drug levels, but only to screen urines for the presence of Cocaine and its metabolites.

Syntron's QuikStrip One Step Cocaine Test consists of a chromatographic absorbent device in which the drug or drug metabolites in the sample compete with a drug conjugate immobilized on a porous membrane support for the limited antibody sites. As the test sample flows up through the absorbent device, the labeled antibody-dye conjugate binds to the free drug in the specimen forming an antibody:antigen complex. This complex competes with immobilized antigen conjugate in the positive reaction zone and will not produce a magenta color band when the drug is above the detection level of 300 ng/ml. Unbound dye conjugate binds to the reagent in the control zone, producing a magenta color band, demonstrating that the reagents and device are functioning correctly.

Here's an analysis of the provided text regarding the QuikStrip One Step Cocaine Test, structured to address your request:

1. Table of Acceptance Criteria and Reported Device Performance

Note: The document does not explicitly state acceptance criteria as numerical thresholds. However, the high performance metrics (near 100%) demonstrated in both in-house and clinical trials strongly imply that high accuracy, sensitivity, and specificity were the desired acceptance criteria for this screening device. The comparison against a gold standard (GC/MS) further reinforces this.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size for Clinical Trial Test Set: 318 samples.
• Data Provenance: Not explicitly stated (e.g., country of origin). The study is referred to as a "clinical trial," implying it's prospective, but this isn't explicitly stated either. The "in-house testing" would likely be retrospective or controlled laboratory settings.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

This information is not provided in the document. The ground truth method (GC/MS) is mentioned, but not the number or qualifications of experts interpreting or validating those GC/MS results, or any subsequent adjudication.

4. Adjudication Method for the Test Set

This information is not provided in the document. The text states: "All positive samples by either screening method were confirmed by GC/MS." and "The results on the 2 discrepant samples clearly demonstrated similar errors by the Emitt II method. Two samples were positive by both GC/MS and QuikStrip, but negative for Cocaine by Emit II®." This indicates comparison to a gold standard and analysis of discrepent results, but not a formal adjudication process involving multiple human readers for consensus.

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No, an MRMC comparative effectiveness study was not done. This device is a rapid, qualitative immunoassay for chemical detection, not an AI-assisted diagnostic tool interpreted by human readers. Therefore, the concept of human readers improving with AI assistance is not applicable here.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done

Yes, a standalone performance evaluation was done. The QuikStrip One Step Cocaine Test is itself a standalone device that provides a qualitative result (presence or absence of a color band, indicating positive or negative for cocaine). Its performance (sensitivity, specificity, accuracy) was measured directly against a gold standard (GC/MS) or a predicate device (Syva EMIT® II), indicating a standalone assessment of its output. There isn't a "human-in-the-loop" interpretation for the device itself; it produces a visual result.

7. The Type of Ground Truth Used

The primary ground truth used was Gas Chromatography/Mass Spectrometry (GC/MS). The document explicitly states: "compared against Syva EMIT® II on samples documented to be positive by GC/MS" and "All positive samples by either screening method were confirmed by GC/MS." GC/MS is considered a definitive confirmatory method for drug concentration.

8. The Sample Size for the Training Set

The document does not provide any information about a specific training set or its size. This device is a chemical immunoassay, not a machine learning model, so the concept of a "training set" in the context of AI/ML is not directly applicable. The "in-house testing" likely served a developmental and validation purpose, but a distinct "training set" as understood in AI is not mentioned.

9. How the Ground Truth for the Training Set Was Established

As there's no mention of a traditional "training set" for an AI/ML model, this question is not applicable in the context of this device. The development process would have involved internal validation and optimization against known samples, likely with GC/MS confirmation, but this isn't presented as a distinct "training set" with established ground truth in the way a machine learning model would have.

Ask a specific question about this device